SSY Group (HKG:2005) obtained production and registration approval for its Vonoprazan Fumarate tablets of 20mg and 10mg strengths from China's National Medical Products Administration, a Wednesday bourse filing said.
The drug is mainly used to treat reflux esophagitis.